Gilead Sciences

GILD

Drug Manufacturers - General · Healthcare

Also trades as: GILD.SW

Price

$146.12

+2.68 (+1.87%)

Market Cap

$181.42B

Exchange

NASDAQ

Winston Score

Winston is serious

Below-average fundamentals — multiple weak pillars.

Data as of Aug 23, 2026 · filings through Jun 30, 2026

How the score breaks down

Quality

Mixed

Growth

Mixed

Cash Flow

Mixed

Stability

Good

Valuation

Data not available

Dividends

Good

Track this stock — start free trial

Winston Score History

The full picture

Gilead Sciences is a biopharmaceutical company that discovers and sells medicines for serious diseases. Its biggest products treat HIV, hepatitis B, hepatitis C, and cancer. Gilead is best known for its HIV drug franchise, which includes Biktarvy — one of the most prescribed HIV treatments in the world — and for developing the first cure for hepatitis C.

Gilead makes money by selling prescription drugs to hospitals, pharmacies, and healthcare systems, primarily in the United States but also across Europe and other global markets. With a gross margin near 80%, its business is highly profitable, and its dominant position in HIV treatment creates a strong competitive moat since patients typically stay on the same regimen for years. The key growth driver going forward is its oncology pipeline, including cell therapy drugs like Yescarta and Tecartus, while the main risk is patent expiration on core HIV drugs, which could open the door to cheaper generic competition.

Politician Trades

17 trades / 12mo

12 Congressional buys and 5 sells on GILD in the last 12 months.

Unlock the full Smart Money Map — every trade plotted on the price chart with politicians, amounts and returns since each trade. Founder's Deal is $57/mo locked for life.

Unlock politician trades

Growth Profile

For growth stock investors

When traditional metrics don't capture the full picture, these are the signals growth stock investors use instead.

Revenue Growth

+10.2% YoY

YoY Growth Rate

Steady revenue growth

EPS Growth

-638.2% YoY

YoY Growth Rate

Earnings declining

R&D Spend

$5.8B/ year

→ Flat (-2% vs prior year)

19.7% of revenue

In line with sector average (18%)

Steady R&D investment year-over-year

Insider Activity

0.2%ownership

→ Flat

Insider ownership roughly steady over the past year

Cash Position

Cash flow positive

$3.2B cash & investments

Quarterly Free Cash Flow

↑ Burn rate improving

Company generates more cash than it spends — no dilution risk from fundraising

Growth + cash flow

Gilead Sciences is a rare growth stock that's already generating positive cash flow while growing at 10%. The Winston Score doesn't fully credit this transition from "burner" to "earner."

The Winston Score above measures business quality today. Growth stocks often score lower because they invest in the future rather than maximising current profits. These metrics show what matters most for evaluating that future.

Share count broadly stable

−0.6% over 4y

The share count has stayed roughly flat over this period — little dilution or buyback activity.

Diluted shares outstanding: 1.26B (2021) → 1.25B (2025)

Score breakdown

Every number that matters to educated investors.

Each metric is explained in plain language so you know exactly what you're looking at. Start your free trial now.

Quality

Profit per sale

Gross Margin

79.8%

Premium pricing power — 79.8% gross margin

Profit after running costs

Operating Margin

-133.2%

Losing money on operations — -133.2%

Return on the money invested

ROCE

-10.5%

Weak — -10.5% return on capital

Negative ROIC means the business is losing money on every dollar invested in it.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Growth

Sales growth

Sales YoY

+5.5%

Slow sales growth (+5.5% YoY)

Profit growth

EPS YoY

-151.4%

Earnings shrinking (-151.4% YoY)

Earnings per share down more than 10%. Either a bad year, or a real decline.

How steady the profit is

EPS Consistency

6/8 quarters

Earnings grew in most of the last 8 quarters

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Cash Flow

Profit that turns into cash

Cash Conversion

N/A

Data not available

Spare cash per sale

FCF Margin

42.6%

Converts sales into free cash efficiently (42.6%)

Free cash flow margin above 20%. Out of every $100 in sales, more than $20 is real cash they keep.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Stability

What it owes vs what it owns

Debt / Equity

0.21

Conservative — low debt load (0.21)

Covers its interest

Interest Cover

N/A

Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Valuation

Price vs profit

P/E Ratio (TTM)

N/M

Negative earnings — P/E not meaningful

Cheaper or dearer next year

P/E vs Forward

N/A

not available

Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Dividends

Dividend

Dividend Yield

2.48%

Moderate income — 2.48% yield

Standard yield zone for stable dividend payers. A meaningful piece of total return.

Dividend record

Dividend Growth

+3.2%

Dividend growing modestly (3.2% YoY)

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

🔒 See full fundamentals and if they are improving or declining — click here for your free trial now.

Start free trial